Chimerix Starts Multi-Dose Trial for Smallpox Infection
Posted on: Wednesday, 12 December 2007, 15:00 CST
Chimerix has initiated a multi-dose trial with its lead drug candidate, CMX001, an oral treatment for smallpox infection. This trial will study the pharmacokinetics and safety of three doses of the drug given to healthy volunteers.
Chimerix has previously demonstrated that single doses of CMX001 provided excellent drug exposure and were well tolerated in healthy volunteers. CMX001 is being developed for smallpox under a licensing agreement with Gilead Sciences. The work is partially funded by a $36.1 million grant awarded to the company by the National Institutes of Allergy and Infectious Disease.
George Painter, president and CEO of Chimerix, said: "In addition to smallpox, we believe that CMX001 has great potential in treating other serious infections such as human papillomavirus and cytomegalovirus."
Source: Datamonitor
Related Articles
- Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
- Chimerix Initiates a Multi-Dose Clinical Trial of the Company's Lead Compound, CMX001, for the Treatment for Smallpox Infection
- Man With Drug-Resistant TB Locked Up
- TB Victim Is Locked Up in Arizona
- Chimerix Buys Chemical Library
- Chimerix and US Army Collaborate on Smallpox Vaccine
- SIGA Technologies Presents Its Smallpox Drug (SIGA-246) to the World Health Organization
- Cancer drug may fight smallpox, study suggests
- Cancer Drug May Fight Smallpox
 |
 |
User Comments (0)
RSS Feeds